{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-015514","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.172753+00:00","generated_at":"2026-05-22T03:45:08.122593+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Puma swings to Q1 profit; NERLYNX revenue up 7% to $43.1M","bullets":["GAAP net income $3.0M ($0.06 EPS) vs net loss $4.8M ($0.10 loss) in Q1 2024.","Non-GAAP adjusted net income $5.0M ($0.10 EPS) vs adjusted loss $2.4M.","Product revenue $43.1M (+7% YoY), royalty revenue $2.9M.","Q2 2025 guidance: net product revenue $48-50M, net income $4-6M.","Cash & securities $93.2M at Mar 31, down from $101.0M at Dec 31."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-015514","json":"https://secwatch.observer/filing/0001437749-25-015514.json","markdown":"https://secwatch.observer/filing/0001437749-25-015514.md","text":"https://secwatch.observer/filing/0001437749-25-015514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774925015514/0001437749-25-015514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774925015514/pbyi20250303_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:45:08.122593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}